中国麻风皮肤病杂志 ›› 2024, Vol. 40 ›› Issue (8): 565-567.doi: 10.12144/zgmfskin202408565

• 临床研究 • 上一篇    下一篇

阿普米司特治疗掌跖脓疱病一例

王娜1,2,杨青1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2024-08-15 发布日期:2024-07-29

Apremilast used in one case of palmoplantar pustulosis

WANG Na1,2, YANG Qing1,2   

  1. 1 Hospital for Skin Diseases, Shandong First Medical University, Jinan 250022, China；2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2024-08-15 Published:2024-07-29

PDF (PC)

78

摘要： 掌跖脓疱病目前尚无标准治疗方案。掌跖脓疱病的传统治疗包括口服阿维A、环孢素及甲氨蝶呤等，常因不良反应而使用受限。除传统外用药物、物理疗法及系统药物外，最近还出现了一些诸如生物制剂、小分子药物等新的治疗方法。本文报道1例阿普米司特超适应症治疗掌跖脓疱病的患者，获得满意的疗效。

关键词: 掌跖脓疱病, 阿普米司特, 小分子药物, PDE4

Abstract: There is currently no standard treatment for palmoplantar pustulosis. Traditional treatments for palmoplantar pustulosis include oral acitretin A, cyclosporine A, and methotrexate, which are often limited due to their adverse effects. In addition to traditional topical drugs, physiotherapy and systemic drugs, new treatments such as biologics and small molecule drugs have recently emerged. This paper reports a case of off-label treatment of palmoplantar pustulosis with apremilast, which achieved satisfactory results.

Key words: palmoplantar pustulosis, apremilast, small molecule drugs, PDE4